Literature DB >> 11574748

Chemoattractant receptors expressed on type 2 T cells and their role in disease.

L Cosmi1, F Annunziato, E Maggi, S Romagnani, R Manetti.   

Abstract

The existence of two functionally distinguished populations among T cells has been established in both mice and humans. Type 1 T helper (Th1) cells are involved in the defense against intracellular bacteria and many viruses, while type 2 Th cells (Th2) are the major actors in the response against parasites and play a central role in allergic inflammation. More recently, several data have suggested that some chemokine receptors are tightly regulated on T cells, and in accordance with this selective expression, Th1 and Th2 cells can be differentially recruited by specific chemokines to the inflammatory sites. Among Th2-associated chemokine receptors, CCR3, CCR4 and CCR8 have been described to play a central role in allergic inflammation. However, CCR3 is mainly expressed on basophils, eosinophils and mast cells, but it is poorly expressed by Th2 cells, and CCR4 is also expressed by Th subsets different from Th2 cells. So far, the chemoattractant receptors which among T cells appear to be selectively expressed by Th2 cells or their subsets are CCR8 and CRTH2. The ligand for CRTH2 is not a chemokine, but is prostaglandin (PG)D2, which is able to attract basophils, eosinophils, Th2 cells and type 2 cytotoxic (Tc2) CD8+ T lymphocytes. The selective expression of CRTH2 on Th2 and Tc2 cells may be useful to develop new therapeutic strategies against allergic diseases and against other immune disorders. Additional studies, however, are required to understand its effective importance in the induction and maintenance of Th2- or Tc2-mediated response and inflammation. Copyright 2001 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11574748     DOI: 10.1159/000053827

Source DB:  PubMed          Journal:  Int Arch Allergy Immunol        ISSN: 1018-2438            Impact factor:   2.749


  7 in total

1.  CC chemokine receptor 4 (CCR4) in human allergen-induced late nasal responses.

Authors:  G Banfield; H Watanabe; G Scadding; M R Jacobson; S J Till; D A Hall; D S Robinson; C M Lloyd; K T Nouri-Aria; S R Durham
Journal:  Allergy       Date:  2010-02-10       Impact factor: 13.146

2.  Expression of CXCL9, -10, -11, and CXCR3 in the tear film and ocular surface of patients with dry eye syndrome.

Authors:  Kyung-Chul Yoon; Chang-Soo Park; In-Cheon You; Hwan-Jun Choi; Kwang-Hoon Lee; Seong-Kyu Im; Hong-Yong Park; Stephen C Pflugfelder
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-10-22       Impact factor: 4.799

3.  Calcitonin gene-related peptide biases Langerhans cells toward Th2-type immunity.

Authors:  Wanhong Ding; Lori L Stohl; John A Wagner; Richard D Granstein
Journal:  J Immunol       Date:  2008-11-01       Impact factor: 5.422

4.  C3a receptor deficiency accelerates the onset of renal injury in the MRL/lpr mouse.

Authors:  Scott E Wenderfer; Hongyu Wang; Baozhen Ke; Rick A Wetsel; Michael C Braun
Journal:  Mol Immunol       Date:  2009-01-23       Impact factor: 4.407

5.  Immune response to Mycobacterium tuberculosis infection in the parietal pleura of patients with tuberculous pleurisy.

Authors:  Gaetano Caramori; Lisa Lasagna; Angelo G Casalini; Ian M Adcock; Paolo Casolari; Marco Contoli; Federica Tafuro; Anna Padovani; Kian Fan Chung; Peter J Barnes; Alberto Papi; Guido Rindi; Giuseppina Bertorelli
Journal:  PLoS One       Date:  2011-07-28       Impact factor: 3.240

6.  Increased frequency of circulating Th22 in addition to Th17 and Th2 lymphocytes in systemic sclerosis: association with interstitial lung disease.

Authors:  Marie-Elise Truchetet; Nicolò C Brembilla; Elisa Montanari; Yannick Allanore; Carlo Chizzolini
Journal:  Arthritis Res Ther       Date:  2011-10-13       Impact factor: 5.156

7.  Immune Biomarkers in Blood from Sarcoma Patients: A Pilot Study.

Authors:  Sarmini Munisamy; Ammu Kutty Radhakrishnan; Premdass Ramdas; Priscilla Josephine Samuel; Vivek Ajit Singh
Journal:  Curr Oncol       Date:  2022-08-05       Impact factor: 3.109

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.